What did @breanna.destini actually say?
She is two days into compounded tirzepatide, describing appetite suppression that kicked in by morning of day two, a migraine and nausea hitting around 5 p.m. on day one, and a near-total loss of hunger by the next morning. She also recommends "more protein and electrolyte you drink, the better you're going to feel." That is essentially the whole medical claim stack here. No dosing numbers, no disease treatment claims. Just a first-person side-effect diary with one practical tip layered on top.
To her credit, she is not selling anything, not citing dubious studies, and not pretending to be an authority. She is documenting what she feels, which is a legitimate use of social media. The mispronunciation of tirzepatide is irrelevant. What matters is whether her descriptions of the drug's effects and her one piece of advice hold up.
Does the science back this up?
Mostly, yes. The timeline she describes, appetite suppression lagging behind the first injection by roughly 24 hours, is consistent with tirzepatide's pharmacokinetics. The nausea and headache pattern she reports are among the most documented early side effects in the clinical literature. Her protein-and-electrolyte tip has real physiological grounding, though it is not a cure for GI symptoms.
In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), gastrointestinal adverse events, primarily nausea, diarrhea, and vomiting, were reported by 44 to 51 percent of participants across tirzepatide dose groups, most concentrated in the early weeks. The migraine she describes is less definitively linked to the drug itself; headache is a listed side effect but can also result from calorie restriction, dehydration, or poor sleep. She experienced all of those triggers simultaneously, so attributing the migraine solely to the drug is premature.
On the B6 compounding angle: there is no peer-reviewed evidence that adding pyridoxine (B6) to compounded tirzepatide reduces nausea meaningfully in this context. It is commonly added by compounding pharmacies, but the evidence base comes from pregnancy-related nausea research, not GLP-1-induced nausea. That is an important distinction nobody seems to be making on TikTok.
What did they get wrong (or right)?
She got the side-effect timeline right. She got the forced eating to manage nausea right. She got the protein focus right. What she did not address, and what her audience genuinely needs to hear, is that compounded tirzepatide is not the same drug as FDA-approved Zepbound or Mounjaro.
Compounded formulations are not FDA-approved. They are mixed by 503A or 503B pharmacies under state board oversight, and quality, potency, and sterility can vary between compounders. The FDA has repeatedly flagged compounded semaglutide and tirzepatide as a concern area. Adding B6 is a common practice, but "common" is not the same as "evidence-based" or "safe." The FDA issued a safety communication in 2024 specifically about compounded GLP-1 products and dosing errors. None of this is her fault for not mentioning it in a casual day-two video, but 25,000 viewers are watching and some will interpret her positive framing as a safety endorsement it was never meant to be.
Her suggestion to force-feed to avoid nausea is actually solid, practical advice that aligns with clinical guidance around eating small, protein-dense meals during GLP-1 initiation.
What should you actually know?
The early-days experience she describes is real and well-documented, but it does not tell you how her body will respond at higher doses, how her weight trajectory will look, or whether compounded tirzepatide is appropriate for anyone watching. GLP-1 receptor agonists are prescription medications that require clinical oversight, not just a telehealth sign-up and a vial in the mail.
A few things her video cannot tell you:
- Whether the compounded version she received matches the concentration stated on the label. FDA audits have found potency discrepancies in compounded GLP-1 products.
- Whether B6 is doing anything meaningful for her nausea, or whether it is a placebo-adjacent additive.
- What her starting dose is or how titration will be managed, which matters significantly for safety.
- Whether postpartum hormonal context affects tirzepatide response. Research here is limited.
If you are considering tirzepatide, the first conversation belongs with a licensed prescriber who has access to your full medical history, not a comment section, however open and well-intentioned the creator may be.